REGULATORY

MHLW Urges Prioritized Delivery of Drugs under Shipment Control to Ishikawa

By Takashi Ebisawa January 22, 2024

The Ministry of Health, Labor and Welfare (MHLW) has issued a notice to relevant pharma groups asking that drugs currently under shipment restrictions be supplied with priority to Ishikawa Prefecture affected by the New Year’s earthquake. However, it stopped short of requesting the outright lifting of such curbs there.

The move came in response to a plea made by Keiji Nakamori, president of the Ishikawa Pharmaceutical Association, who met directly with Health Minister Keizo Takemi during his visit to the Ishikawa capital of Kanazawa on January 18.

During the meeting, Mr Nakamori explained that medicines were lacking in disaster-struck areas and sought emergency measures such as lifting shipment controls in Ishikawa to enable the securing of necessary drugs. The minister responded to this plea by instructing MHLW officials to appropriately take care of this matter.

On receiving this instruction, the MHLW issued a notice later in the day to the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), the Federation of Japan Pharmaceutical Wholesalers Association (JPWA), and an association of drug distributors in Ishikawa. In the notice, the ministry stated that stakeholders in the quake-hit areas have voiced concerns over the stable supplies of ethical medicines and called on prioritized deliveries of shipment-restricted drugs in order to meet the demands of those regions.

The distributor association of Ishikawa and the JPWA had made a similar request to the FPMAJ on January 9, asking for prioritized drug supplies to the Hokuriku region in central Japan, including Ishikawa. The latest MHLW notification is intended to ensure that this request comes through.

Although the Ishikawa Pharmaceutical Association had sought the lifting of shipment restrictions, the MHLW’s notice was confined to asking the industry to prioritize supplies of the relevant products.

The MHLW said to Jiho on January 19, “As shipment controls are determined by respective makers according to their shipment volume and demand, it is difficult for the government to reverse this across the board.” The ministry asked for understanding, saying that the wording in the notice was the most it could use within its power.

Still, the MHLW expects that the notice will bring about actions almost equivalent to the lifting of curbed shipments, with the next focus to be on how manufacturers and wholesalers will respond to this call.

Related Article

REGULATORY

By Izuru Ando

Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…

By Philip Carrigan

Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

By Izuru Ando

Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…